0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Surgical Excision After Neoadjuvant Therapy With Vismodegib for a Locally Advanced Basal Cell Carcinoma and Resistant Basal Carcinomas in Gorlin Syndrome

Anne Lynn S. Chang, MD; Scott X. Atwood, PhD; Danielle M. Tartar, PhD; Anthony E. Oro, MD
JAMA Dermatol. 2013;149(5):639-641. doi:10.1001/jamadermatol.2013.30.
Text Size: A A A
Published online

Extract

Vismodegib is useful to treat locally advanced or metastatic basal cell carcinomas (BCCs),1 but to our knowledge, its use as a neoadjuvant to shrink BCCs before surgery has not been reported. This case illustrates the role of vismodegib as a neoadjuvant agent. In addition, this case highlights the fact that a patient with Gorlin syndrome can develop resistant BCCs while taking vismodegib, a phenomenon not widely recognized although recently reported.2

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Clinical and computed tomographic (CT) images of a 55-year old man with Gorlin syndrome. The patient's locally advanced basal cell carcinoma (BCC) regressed under treatment with neoadjuvant vismodegib but demonstrated areas of drug resistance. Residual BCC and resistant areas were excised. A, Locally advanced BCC on the right scalp prior to treatment. B, Tumor shrinkage after 51 weeks of vismodegib therapy showing development of 2 areas of resistant BCC (arrowheads). C, After surgical excision, the patient received full-thickness skin grafts to cover the right scalp and the right tragus/external auditory canal, shown here at 2 months after surgery. D, Pretreatment axial CT image shows bony defects of the calvarium under the BCC. E, Posttreatment CT scan shows shrinkage of the calvarial defect after vismodegib therapy.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Vismodegib-resistant basal cell carcinoma (BCC) tumors (hBCCSmos) show increased levels of Gli transcription factors and pik3c (phosphatidylinositol 3-kinase catalytic) enzymes. Tumor hBCCSmoR1 was on the tragus and hBCCSmoR2 was on the posterior scalp. A, Compared with normal skin from the same patient, both resistant tumors showed elevation of pik3c (isoform 2a) level. Tumor hBCCSmoR2 showed elevations of Gli1, ptch1 protein, and all isoforms of pik3c levels. Analysis was undertaken by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) performed in triplicate (RNeasy Mini Kit; Qiagen). Transcripts were quantified in triplicate using Brilliant II SYBR Green qRT-PCR Master Mix Kit (Agilent Technologies) with primers to human GLI1,4PTCH1,4 and PIK3C isoforms.5 B, Immunofluorescence analysis performed on formalin-fixed, paraffin-embedded tissue shows that Gli1 protein levels are elevated in tumor hBCCSmoR2 but not in hBCCSmoR1 compared with normal skin from the same patient. The top row of images depicts tissues viewed without fluorescence; the bottom row of images depicts tissues viewed with fluorescence. Immunofluorescence studies were performed with anti-Gli1 (1:500; Cell Signaling) and Hoechst 33342 (1:10 000; Invitrogen). Confocal images were acquired on a Leica SP2 AOBS Laser Scanning Microscope with an HCX PL APO 63X oil-immersion objective.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();